Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.56 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | ALPL | P05186 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2148753 | 0.80 | GABRP (0.51) | BAZ2BBAZ2AALDH1A1GAALMNA | |
| SCHEMBL70354 | 0.79 | BAZ2B (0.71) | BAZ2BBAZ2AALDH1A1GAALMNA | |
| SCHEMBL21060866 | 0.79 | BAZ2B (0.56) | BAZ2BBAZ2AALDH1A1GAALMNA | |
| SCHEMBL162449 | 0.79 | BAZ2B (0.56) | BAZ2BBAZ2AALDH1A1GAALMNA | |
| SCHEMBL1298467 | 0.78 | BAZ2B (0.54) | BAZ2BBAZ2AALDH1A1GAALMNA | |
| SCHEMBL1298188 | 0.78 | BAZ2B (0.54) | BAZ2BBAZ2AALDH1A1GAALMNA | |
| SCHEMBL20763689 | 0.78 | BAZ2B (0.54) | BAZ2BBAZ2AALDH1A1GAALMNA | |
| SCHEMBL14267776 | 0.78 | BAZ2B (0.54) | BAZ2BBAZ2AALDH1A1GAALMNA | |
| SCHEMBL9918752 | 0.78 | BAZ2B (0.54) | BAZ2BBAZ2AALDH1A1GAALMNA | |
| SCHEMBL13346251 | 0.78 | BAZ2B (0.54) | BAZ2BBAZ2AALDH1A1GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001039766-A2 | SCREENING INVERTEBRATE PHEROMONES FOR THERAPEUTIC ACTIVITY | ALYDAR PHARMACEUTICALS LTD. (IL) | 2001-06-07 | — | — | WO | claimed |
| EP-3988555-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | AbbVie Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| US-11053260-B2 | Tri-cycle compound and applications thereof | FUJIAN COSUNTER PHARMACEUTICAL CO., LTD. (CN) | 2021-07-06 | — | — | US | disclosed |
| EP-3587420-B1 | TRI-CYCLE COMPOUND AND APPLICATIONS THEREOF | FUJIAN COSUNTER PHARMACEUTICAL CO LTD (CN) | 2021-03-31 | — | — | EP | disclosed |
| US-20200247819-A1 | TRI-CYCLE COMPOUND AND APPLICATIONS THEREOF | FUJIAN AKEYLINK BIOTECHNOLOGY CO., LTD. (CN) | 2020-08-06 | — | — | US | disclosed |
| WO-2019042267-A1 | PYRROLE-2-FORMAMIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND APPLICATIONS THEREOF | 中国医学科学院药物研究所 | 2019-03-07 | — | — | WO | disclosed |
| WO-2019035914-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019035899-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019035927-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| US-9758509-B2 | Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors | ALLERGAN, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-5849693-A | Cyclic compounds linked by a heterocyclic ring useful as inhibitors of platelet glycoprotein IIb/IIIa | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-12-15 | — | — | US | disclosed |
| EP-0859035-A1 | Spray-type insecticidal paint and manufacturing process thereof | Kukbo Pharma. Co., Ltd. (KR) | 1998-08-19 | — | — | EP | disclosed |
| US-5773411-A | CARDIOVASCULAR DISORDERS AND BRAIN DISORDERS AND COAGULANTS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-06-30 | — | — | US | disclosed |
| US-5563158-A | CARDIOVASCULAR DISORDERS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-10-08 | — | — | US | disclosed |
| EP-0475160-B1 | Preparation for drug application in minute droplet form | IDEA AG (DE) | 1996-02-14 | — | — | EP | disclosed |
| EP-0672059-A1 | CYCLIC COMPOUNDS LINKED BY A HETEROCYCLIC RING USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995018111-A1 | COMPOUNDS CONTAINING BASIC AND ACIDIC TERMINI USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-07-06 | — | — | WO | disclosed |
| WO-1994011398-A1 | CYCLIC COMPOUNDS LINKED BY A HETEROCYCLIC RING USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-05-26 | — | — | WO | disclosed |
| EP-0475160-A1 | Preparation for drug application in minute droplet form | Cevc, Gregor, Prof. Dr. (DE) | 1992-03-18 | — | — | EP | disclosed |
| WO-1992003122-A1 | PREPARATION FOR APPLICATION OF ACTIVE SUBSTANCES IN THE FORM OF MINIMUM-SIZED DROPLETS | CEVC GREGOR (DE) | 1992-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247819-A1 | TRI-CYCLE COMPOUND AND APPLICATIONS THEREOF | SLC10A1, NR1H4, HAVCR2 | BAZ2B 501/4885BAZ2A 918/4885ALDH1A1 2611/4885 |
| US-11053260-B2 | Tri-cycle compound and applications thereof | SLC10A1, NR1H4, HAVCR2 | BAZ2B 501/4885BAZ2A 918/4885ALDH1A1 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.